Clinical trials: B Cell ALL
Relapsed Pediatric ALL, Hematopoietic Cell Transplantation
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
The purpose of this study is to learn more about newer methods of transplanting blood cells donated by a partially matched family member to children with high-risk CD19 positive leukemia ALL.
- Conditions
- Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy
- Trial name
- NCT07257419
- Testing
- Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- St. Jude Children's Research Hospital
Diffuse Large B Cell Lymphoma, Diffuse Large B-Cell Lymphoma Recurrent
RICE-ibrutinib in Relapsed DLBCL
This is a multicentre, open-label, phase II study of ibrutinib 560 mg in combination with R-ICE for treatment of transplant-eligible relapsed/refractory diffuse large B-cell lymphoma.
- Trial name
- NCT02955628
- Testing
- Ibrutinib-RICE
- Where
- 4 sites in Singapore
- Volunteers
- 34 people
- Sponsor
- Singapore General Hospital
Hepatocellular Carcinoma
Immunotherapy of Advanced Hepatitis B Related Hepatocellular Carcinoma With γδT Cells
To evaluate the safety, tolerability and efficacy of autologous γδT cells in the treatment of advanced hepatitis B-related hepatocellular carcinoma.
- Trial name
- NCT04032392
- Testing
- autologous γδT cells
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Beijing 302 Hospital
Diffuse Large B Cell Lymphoma
Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive
To evaluate the efficacy and safety of selinexor combined with BEAM pretreatment regimen in ASCT of recurrent and refractory DLBCL patients with immunohistochemical positive for MYC
- Trial name
- NCT06652139
- Testing
- selinexor combined with BEAM regimen, BEAM regimen
- Volunteers
- 82 people
- Sponsor
- Ruijin Hospital
Diffuse Large B-cell Lymphoma
Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
The purpose of this study is to determine the efficacy and safety of ofatumomab in combination with ICE chemotherapy in subjects with relapsed/refractory DLBCL following failure to combination rituximab and anthracycline based…
- Trial name
- DLBL (NCT02412267)
- Testing
- O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)
- Where
- Singapore
- Volunteers
- 17 people
- Sponsor
- National Cancer Centre, Singapore
B Cell Leukemia, B Cell Lymphoma
A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
CD19-directed CAR-T cell therapy has shown promising results for the treatment of relapsed or refractory B-cell malignancies; however, a subset of patients relapse due to the loss of CD19 in tumor cells.
- Trial name
- NCT03398967
- Testing
- Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chinese PLA General Hospital
Primary Mediastinal B-Cell Lymphoma
A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma
A non-profit study designed with the aim of analysing the phenotype and molecular characteristics (central review) and evaluating prospectively the role of PET-scans in the management of primary mediastinal lymphoma treated with…
- Trial name
- NCT00944567
- Where
- 20 sites in Italy, Spain and 2 more
- Volunteers
- 125 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL.
- Conditions
- Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle-cell Lymphoma
- Trial name
- NCT02631044
- Testing
- JCAR017 (lisocabtagene maraleucel) single-dose schedule, JCAR017 (lisocabtagene maraleucel) 2-dose schedule
- Where
- 14 sites in United States
- Volunteers
- 387 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
This phase II trial studies the side effects and how well blinatumomab and combination chemotherapy or dasatinib, prednisone, and blinatumomab work in treating older patients with acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent Acute Lymphoblastic Leukemia
- Trial name
- NCT02143414
- Testing
- Biopsy Procedure, Biospecimen Collection, Blinatumomab
- Where
- 195 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, B-Cell
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
The purpose of this study is to find the highest dose of a new drug, in combination with standard drugs, which can be tolerated without causing very severe side effects.
- Trial name
- NCT04161248
- Testing
- Venetoclax, Rituximab Injection, Rituximab SC
- Where
- 4 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Canadian Cancer Trials Group
Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
Adult patients with r/r acute lymphoblastic leukemia (ALL) (stratum I), r/r Non-Hodgkin's lymphoma (NHL) including chronic lymphocytic leukaemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) or mantle…
- Conditions
- Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT03676504
- Testing
- CD19.CAR T Cells, Fludarabine, Cyclophosphamide
- Where
- 2 sites in Germany
- Volunteers
- 68 people
- Sponsor
- University Hospital Heidelberg
Indolent B-Cell Non-Hodgkin Lymphoma
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab with or without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory…
- Trial name
- NCT03571568
- Testing
- BI-1206, Rituximab, Acalabrutinib
- Where
- 27 sites in United States, Brazil and 4 more
- Volunteers
- 140 people
- Sponsor
- BioInvent International AB
Diffuse Large B-cell Lymphoma
Pola-ZR2P in Previously Untreated DLBCL
The goal of this phase 2 trial is to test the safety and efficacy of Pola-ZR2P as induction therapy in patients with DLBCL.
- Trial name
- NCT06664411
- Testing
- Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Navy General Hospital, Beijing
Leukemia, Lymphocytic, Chronic, B-Cell
A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia
The purpose of this study is to confirm the efficacy and safety of fludarabine phosphate administered with dose increasing in 6 cycles (1 cycle: 5 treatment days every 28 days) in untreated chronic lymphocytic leukemia (CLL)…
- Trial name
- NCT00220311
- Testing
- Fludarabine Phosphate (Fludara)
- Volunteers
- 10 people
- Sponsor
- Genzyme, a Sanofi Company
Marginal Zone Lymphoma
Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
This study aims to evaluate real-world treatment modalities and their corresponding effectiveness and safety in Chinese patients with marginal zone lymphoma, while also exploratively analyzing patient characteristics and…
- Trial name
- MOTIVE (NCT06534463)
- Testing
- All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Ruijin Hospital
Diffuse Large B Cell Lymphoma Refractory
Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas
This is an investigator-initiated, open-label, single-arm, multicenter, Phase II clinical study. The study is designed to evaluate the safety and potential effectiveness of glofitamab in adults with their disease, diffuse large…
- Trial name
- GLO-PACT (NCT07387848)
- Testing
- Glofitamab
- Volunteers
- 40 people
- Sponsor
- American University of Beirut Medical Center
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B-cell Non-hodgkin Lymphoma
CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies
It is a single-arm, open-label clinical study to assess the safety and efficacy of the Anti-CD19 Universal CAR-T Cells injection for patients with CD19+ refractory/relapsed B cell acute lymphoblastic leukemia and B cell…
- Trial name
- NCT05105867
- Testing
- Anti-CD19 Universal CAR-T Cells injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Chronic Lymphocytic Leukemia
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
The purpose of the study is to evaluate the ability of Rituximab maintenance therapy to prolong progression free survival in patients with chronic lymphocytic leukemia, who responded to a Rituximab induction therapy.
- Trial name
- NCT01118234
- Testing
- Rituximab
- Where
- 22 sites in Austria, Czechia and 1 more
- Volunteers
- 256 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Diffuse Large B Cell Lymphoma
A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma
A phase II trial of ifosfamide, etoposide, cytarabine, and methotrexate (IVAM) chemotherapy for refractory or relapsed diffuse large B cell lymphoma
- Trial name
- IVAM (NCT03383406)
- Testing
- Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy
- Volunteers
- 30 people
- Sponsor
- Asan Medical Center
Chronic Lymphocytic Leukemia, Thrombocytopenia
Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)
The aim of this study is to find the appropriate dose of eltrombopag in thrombocytopenic CLL patients, that shortens the duration of the thrombocytopenia and achieves platelet count of ≥ 100/nl prior to the start of chemotherapy…
- Trial name
- NCT01397149
- Testing
- Eltrombopag
- Where
- 10 sites in Austria, Germany
- Volunteers
- 4 people
- Sponsor
- University of Ulm
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.